• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

    1/18/22 8:00:00 AM ET
    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VBLT alert in real time by email
    • CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111)
    • Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing

    TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer (CCO). Mr. Trudeau will be responsible for all commercialization activity for ofranergene obadenovec (`ofra-vec`, or VB-111). His appointment further advances VBL's strategic plan to become a commercial organization and establish operations in the United States.

    "We are delighted to have Matt join our leadership team," said Dror Harats, M.D., Chief Executive Officer of VBL. "Matt has the perfect background for this new position, with significant leadership experience in the launch and marketing of complex biologics in oncology and gene therapy. As our lead therapeutic candidate, ofra-vec, advances towards a readout of the progression free survival co-primary endpoint from the ongoing OVAL Phase 3 trial expected in the second half of 2022, Matt's addition as Chief Commercial Officer is a key step in establishing commercial preparedness."

    Matthew Trudeau commented, "I am very pleased to join VBL at this important time. Ofra-vec is an exciting late-stage asset that may offer important value and a differentiated solution to oncology patients and their providers. I am excited to have the opportunity to lead a best-in-class commercial launch that is meaningful to patients and other important stakeholders."

    Matthew Trudeau brings over 25 years of U.S. and international experience commercializing complex biological products. He has experience leading all aspects of commercial practice at both small and large biotech companies. From 2016 to 2021, he held positions of increasing responsibility at bluebird bio, culminating in his appointment as Head of the U.S. business team. In this role, he led the design and implementation of bluebird's commercial operating model and was accountable for all aspects of U.S. commercialization for an innovative gene therapy portfolio. From 2010 to 2016, he was employed at Biogen where he led Asia-Pacific business operations for a portfolio of biologics targeting neurologic and hematologic diseases. At Biogen, he also led global strategic design and implementation of the company's first companion diagnostic platform. Mr. Trudeau began his career at Genzyme, where he advanced through sales and marketing roles of increasing impact in the diagnostics and surgical oncology segments. He holds a M.Sc degree in molecular biology from Northeastern University and a B.A. degree in biochemistry from Colby College.

    About VBL Therapeutics

    Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late-clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for difficult-to-treat malignant solid tumors and immune or inflammatory indications. VBL's novel VTS™ gene-based platform and antibody-based monocyte targeting technology enable the creation of a pipeline of programs that harness the body's innate biological processes to provide unique solutions for significant unmet medical needs. VBL's lead oncology product candidate, ofranergene obadenovec (`ofra-vec`, or VB-111), is an investigational, first-in-class, targeted anti-cancer gene-based agent in development to treat a wide range of solid tumors. Ofra-vec is currently being studied in a Phase 3 registration-enabling clinical trial (NCT03398655) for platinum-resistant ovarian cancer. To learn more about VBL, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

    Forward Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding the timing of completion of enrollment and progression free survival (PFS) data readout for the OVAL Phase 3 clinical trial, the ability of such data to support a biologics license application (BLA) filing, the ofra-vec (VB-111) value proposition and its ability to obtain regulatory approval and be commercialized, and VBL's ability to become a commercial organization, among others. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with the development of pharmaceutical product candidates, including risks associated with conducting clinical trials such as the OVAL study, and risks related to obtaining regulatory approval for ofra-vec and risks associated with commercialization of pharmaceutical products, once approved, along with the risk that historical clinical trial results may not be predictive of future trial results, and other risks inherent in pharmaceutical product development. A further list and description of these risks, uncertainties and other risks can be found in VBL's regulatory filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 20-F for the year ended December 31, 2020, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

    CONTACT:

    Daniel Ferry

    LifeSci Advisors

    +1 (617) 430-7576

    [email protected]



    Primary Logo

    Get the next $VBLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VBLT

    DatePrice TargetRatingAnalyst
    7/20/2022Outperform → Perform
    Oppenheimer
    7/20/2022Buy → Neutral
    H.C. Wainwright
    7/18/2022$5.50Outperform
    Oppenheimer
    4/28/2022$5.00Buy
    Chardan Capital Markets
    More analyst ratings

    $VBLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vascular Biogenics Ltd. (Amendment)

      SC 13G/A - Notable Labs, Ltd. (0001603207) (Subject)

      1/11/24 5:22:04 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Vascular Biogenics Ltd.

      SC 13D - Notable Labs, Ltd. (0001603207) (Subject)

      10/19/23 1:34:02 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vascular Biogenics Ltd.

      SC 13G - Vascular Biogenics Ltd. (0001603207) (Subject)

      2/1/22 4:20:25 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Vascular Biogenics Ltd.

      DEF 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/16/24 9:00:13 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Vascular Biogenics Ltd.

      PRE 14A - Notable Labs, Ltd. (0001603207) (Filer)

      2/5/24 5:00:08 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics Ltd. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      2/2/24 4:05:36 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Leadership Updates

    Live Leadership Updates

    See more

    $VBLT
    Financials

    Live finance-specific insights

    See more

    $VBLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance
    • VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

      CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced the appointment of Matthew Trudeau to the newly created position of Chief Comm

      1/18/22 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

      TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in building and financing private and public biotechnology companies. In connection with the appointment, VBL established U.S. operations in New York, which will be managed by Mr. Backenroth, and he will be responsible for leading the company's future financing and business development activities to support the company's growth initiatives. Mr. Backenroth succeeds Mr. Amos Ron, who is retiring but will cont

      10/5/21 8:00:00 AM ET
      $NBSE
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

      Merger will create Nasdaq-listed, clinical-stage therapeutic platform company developing new precision medicines for patient populations selected through Notable's proprietary Predictive Precision Medicines Platform ("PPMP") Notable's validated PPMP combines multi-dimensional biological assays and machine learning to bio-simulate a patient's cancer treatment and predict their clinical response to the actual treatment Notable has applied its PPMP to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia ("AML"); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients expected in 3Q 2024 Leading healthtech-focus

      2/23/23 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

      OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced financial results for the first quarter ended March 31, 2022, and provided a corporate update. "We continue to execute on our development and strategic objectives, which we believe have positioned us for a potentia

      5/17/22 7:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting

      Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its shareholders voted to approve the previously announced proposed merger (the "Merger") with Notable Labs, Inc. ("Notable"), at the annual and special meeting (the "Meeting") which took place today, October 12, 2023. Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger. VBL's shareholders also voted t

      10/12/23 9:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting

      MODI'IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), reminds its shareholders to vote in favor of the previously announced proposed merger (the "Merger") with Notable Labs ("Notable") at the annual and special meeting (the "Meeting") for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of number of ordinary shares, nominal value of NIS 0.01 ("VBL Ordinary Shares") held, are encouraged to vote "FOR" the Merger and related proposals described in the definitive proxy statement/prospectus/information statement previously filed by VBL with the U.S. Securities and Exchange Commission (the "SEC") in connection with

      10/4/23 8:00:00 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Feinberg Peter

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:45 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Patsi Tuomo

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:20 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Galen Michele

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:04:43 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vascular Biogenics downgraded by Oppenheimer

      Oppenheimer downgraded Vascular Biogenics from Outperform to Perform

      7/20/22 9:01:50 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Vascular Biogenics from Buy to Neutral

      7/20/22 7:39:29 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Vascular Biogenics with a new price target

      Oppenheimer resumed coverage of Vascular Biogenics with a rating of Outperform and set a new price target of $5.50

      7/18/22 9:22:46 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care